International Journal of Pharmacology1811-77751812-5700Asian Network for Scientific Information10.3923/ijp.2022.842.849SongJing PengJing LiuXiaoyun ZhouDexi YangChunyan LuanJiajie 42022184Background and Objective: In recent years, domestic and foreign scholars have carried out a large number of clinical trials with adenosine triphosphate tumour chemosensitivity assay in vitro (ATP-TCA). This study explores the guiding significance of ATP-TCA in the treatment of Non-Small Cell Lung Cancer (NSCLC) patients with pleural effusion in our hospital. Materials and Methods: In the experiment group, the cancer cells in patients with pleural effusion were tested for ATP-TCA and the sensitivity of the drug results would be sent to the clinicians who would adjust the medication based on the results. In the control group, the clinician used traditional treatment, without intervention. After the treatment and discharge, the patients were followed up once a month to observe the difference in survival rate and quality of life between the 2 groups. At last, we perform statistical analysis on laboratory data and patient clinical data. Results: The sensitivity of the cancer cells in the pleural effusion was significantly different and the use rates of the drugs had significant differences. Meanwhile, the above 2 sets of data did not show a good correlation. Besides, the survival rate of patients in the experimental group was significantly higher than that of patients in the control group but there was no significant difference in the quality of life between the 2 groups after treatment. Conclusion: The choice of anti-tumour drugs by clinicians was relatively random. ATP-TCA had clinical guiding significance for the choice of anti-tumour drugs for NSCLC patients combined with pleural effusion.]]>Vasan, N., J. Baselga and D.M. Hyman,2019575299309Whitehouse, P.A., L.A. Knight, F.D. Nicolantonio, S.J. Mercer, S. Sharma and I.A. Cree,2003ex vivo ATP-tumor chemosensitivity assay (ATP-TCA).]]>14369375Kurbacher, C.M., O.M. Grecu, U. Stier, T.J. Gilster and M.M. Janát et al.,20112011pp: 221-230pp: 221-230Qi, C.J., Y.L. Ning, Y.L. Zhu, H.Y. Min, H. Ye and K.Q. Qian,2009In vitro chemosensitivity in breast cancer using ATP-tumor chemosensitivity assay.]]>3217371742Su, J.L., C.H. Wang, H.G. Kang, J. Zhang and B.Z. Wang et al.,20171435103514Xia, F., S. Ma, Y. Bian, D. Yu and W. Ma et al.,2020in vitro chemosensitivity using ATP-TCA with patient clinical outcomes in acute myeloid leukemia.]]>85509515Glaysher, S., D. Yiannakis, F.G. Gabriel, P. Johnson and M.E. Polak et al.,2009in vitro chemosensitivity of non-small cell lung cancer (NSCLC).]]>2009Pakunlu, R.I., Y. Wang, W. Tsao, V. Pozharov, T.J. Cook and T. Minko,20046462146224Sun, M., C. Yang, J. Zheng, M. Wang and M. Chen et al.,201528171182Zhang, Y., Q. Zhao, Y. Jiang, Z. Yuan and L. Yang,20133812231227Herbst, R.S., D. Morgensztern and C. Boshoff,2018553446454Chen, Z., S. Zhang, S. Ma, C. Li and C. Xu et al.,2018in vitro chemosensitivity and correlation with clinical outcomes in lung cancer using the ATP-TCA.]]>18139145Sharma, S., M.H. Neale, F.D. Nicolantonio, L.A. Knight and P.A. Whitehouse et al.,20032003Cree, I.A., C.M. Kurbacher, A. Lamont, A.C. Hindley and S. Love,20071810931101Ling, Z.Q., C.J. Qi, X.X. Lu, L.J. Qian and L.H. Gu et al.,201233401406Arsenijevic, M., M. Milovanovic, S. Jovanovic, N. Arsenijevic, B.S. Markovic, M. Gazdic and V. Volarevic,2017In vitro and in vivo anti-tumor effects of selected platinum(IV) and dinuclear platinum(II) complexes against lung cancer cells.]]>22807817Watanabe, S., N. Nitta, S. Ohta, A. Sonoda and H. Otani et al.,201235399405Cheng, X., S. Wei, H. Zhang, S. Xue, W. Wang and K. Zhang,20182018Faury, S., M. Koleck, J. Foucaud, K. M’Bailara and B. Quintard,201710018071819de Tejada, M.G.S., A. Bilbao, M. Baré, E. Briones, C. Sarasqueta, J.M. Quintana and A. Escobar,20172612631269